A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data

In several neurodegenerative diseases, like Huntington's disease (HD), treatments are still lacking. To determine whether a treatment is effective, sensitive disease progression biomarkers are especially needed for the premanifest phase, since this allows the evaluation of neuroprotective treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Beste, Christian, Stock, Ann-Kathrin, Ness, Vanessa, Hoffmann, Rainer, Lukas, Carsten, Saft, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647202/
https://www.ncbi.nlm.nih.gov/pubmed/23652721
http://dx.doi.org/10.1038/srep01797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647202/
https://www.ncbi.nlm.nih.gov/pubmed/23652721
http://dx.doi.org/10.1038/srep01797

Ejemplares similares